Johnson & Johnson Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31)
Johnson & Johnson (JNJ) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) of $62.21 as of 2012-01-01, per its 10-K filed 2012-02-23.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2012-02-23
- 2012-01-01: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $62.21.
- 2011-01-02: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $62.62.
- 2010-01-03: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $58.32.
- 2008-12-28: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $61.80.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) |
|---|---|
| 2012-01-01 | $62.21 10-K · filed 2012-02-23 |
| 2011-01-02 | $62.62 10-K · filed 2012-02-23 |
| 2010-01-03 | $58.32 10-K · filed 2012-02-23 |
| 2008-12-28 | $61.80 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |